Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02787369 · ClinicalTrials.gov registry record · Phase 1
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
A Phase 1 study of Recurrent Chronic Lymphoid Leukemia, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT02787369: Active Phase 1 study of Recurrent Chronic Lymphoid Leukemia, sponsored by Dana-Farber Cancer Institute.
NCT02787369 is a Phase 1 study of Recurrent Chronic Lymphoid Leukemia that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02787369, a Phase 1 study of Recurrent Chronic Lymphoid Leukemia, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying a drug called ACY-1215 in combination with ibrutinib or idelalisib as a possible treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).
Primary Outcome
Determining Maximum Tolerated Dose
Conditions Studied
Interventions
- DRUG Ibrutinib
- DRUG Idelalisib
- DRUG ACY-1215
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-05 |
| Est. Completion | 2027-04 |
| Phase | Phase 1 |
What the registry record for NCT02787369 still lists
NCT02787369 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Recurrent Chronic Lymphoid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Ibrutinib is the first listed.
NCT02787369 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02787369 about?
NCT02787369 is a clinical study titled "ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL". This research study is studying a drug called ACY-1215 in combination with ibrutinib or idelalisib as a possible treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).
What is the current status of trial NCT02787369?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2016-05. Estimated completion is 2027-04.
What conditions does trial NCT02787369 study?
This clinical trial studies the following conditions: Recurrent Chronic Lymphoid Leukemia.
What interventions are being tested in trial NCT02787369?
The interventions under investigation include: Ibrutinib (DRUG), Idelalisib (DRUG), ACY-1215 (DRUG).
Who is sponsoring clinical trial NCT02787369?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02787369 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02787369's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia